25 May 2023 07:00
25 May 2023
Nuformix plc
("Nuformix" or the "Company")
Change of Auditor
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Kreston Reeves LLP ("Kreston Reeves") as auditor to the Company. The appointment of Kreston Reeves will be subject to approval by shareholders at the next Annual General Meeting of the Company.
Enquiries:
Nuformix plc |
|
Dr Dan Gooding, Executive Director
| Via IFC Advisory
|
Stanford Capital Partners Limited |
|
Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
John Howes (Corporate Broking) | +44 (0) 20 3650 3652
|
IFC Advisory Limited |
|
Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
Nuformix (NFX)